Case Report: Convalescent Plasma Achieves SARS-CoV-2 Viral Clearance in a Patient With Persistently High Viral Replication Over 8 Weeks Due to Severe Combined Immunodeficiency (SCID) and Graft Failure

Abstract

We describe the unique disease course and cure of SARS-CoV-2 infection in a patient with SCID and graft failure. In absence of a humoral immune response, viral clearance was only achieved after transfusion of convalescent plasma. This observation underscores the necessity of the humoral immune response for SARS-CoV-2 clearance.

Introduction

We describe a 25-year-old female patient with severe combined immunodeficiency (SCID) due to a RAG1 variant (1, 2) with persistently high SARS-CoV-2-RNA concentrations in respiratory samples over 60 days. Immunocompromised patients have not only an increased risk of acquiring severe Corona virus disease 2019 (COVID-19) (3, 4) but may fail to achieve viral clearance with prolonged shedding of viable virus (5, 6).

Our patient was first treated with remdesivir and subsequently received convalescent plasma (CP), which achieved sustained viral clearance.

Case Description and Diagnostic Assessment

The patient was diagnosed with T^-/B^-/NK⁺ SCID and received unconditioned haploidentical hematopoietic stem cell transplantation (HSCT) from her father at 4 months of age (7). Due to incomplete immune reconstitution with poor T cell- and no B cell-engraftment she received a stem cell boost without preconditioning at 4 years of age, repetitive donor lymphocyte infusions (5 times, last infusion 11/2019) and regular immunoglobulin substitution therapy.

She suffered from recurrent bronchopulmonary infections and chronic obstructive pulmonary disease. Due to progressive graft failure she was scheduled for another HSCT.

After a close friend tested positive for SARS-CoV-2, testing was performed while she was asymptomatic and results were positive for SARS-CoV-2 on 30^th of April 2020 (day 0). Since patients with SCID are prone to severe systemic viral infections (e.g. cytomegalovirus, adenovirus, parainfluenza virus) (8–10) she was admitted for clinical observation.

Upon admission, her physical examination, vital signs, chest radiography and a CT scan were unremarkable (Figure 1). The patient experienced a mild headache for one day but no other COVID-19 associated symptoms. The initial SARS-CoV-2-RNA concentration in the nasopharyngeal swab was 4.89 x 10⁸ copies/ml. SARS-CoV-2 could not be PCR-amplified from the patient’s EDTA blood, bone marrow, urine and stool samples. Over the course of 30 days, the patient did not develop any overt symptoms despite persistent high-level viral replication.

Figure 1

On initial admission (day 0) the patient had a reduced neutrophil count (nadir of 115/µl on day 4), lymphopenia (389/µl) with reduced T-cells 250/µl (CD4⁺CD45RA⁺T-cells 6.4/µl; CD4⁺CD45RO⁺T-cells 63/µl; CD8⁺CD45RA⁺T-cells 29/µl; CD8⁺CD45RO⁺T-cells 68/µl). NK-cells (CD3^-CD56⁺) were reduced to 1.3% (4.8/µl). Monocytes were 285/µl and B-cells were absent, which was in line with undetectable IgA and IgM levels (IgG was substituted). Neutrophils were reduced shortly after infection and recovered preceding development of pneumonia (Table 1). The patient received prophylactic antibiotic and antifungal treatment.

On d33 of follow-up the patient presented without overt symptoms, but oxygen saturation was 93% and a CT-scan showed signs of COVID-19 pneumonia (Figure 1). SARS-CoV-2-RNA was 1.95 x 10⁷ and 4.07 × 10⁶ copies/ml in nasopharyngeal and bronchial fluid samples, respectively. Thus, COVID-19 pneumonia was diagnosed and the patient received remdesivir (200 mg i.v. on d33, 100 mg/d i.v. d34-42) over 10 days (11). Remdesivir treatment reduced viral concentrations from 1.95 x 10⁷ copies/ml to 5.35 x 10⁴ copies/ml (Figure 2). Whole genome sequencing of SARS-CoV-2 showed no remdesivir resistance development. Clinical symptoms of pneumonia improved, however, virus concentrations increased again to levels of 1.48 x 10⁸ copies/ml on d54. To achieve viral clearance, the patient received two units of convalescent plasma (CP, 250 ml each) from donor-1 on day 55 (12). This contained spike-specific IgA- and IgG-antibodies (OD-ratios were 1.94 and 3.26, respectively) and had a neutralizing antibody titer (NT-titer) of 1:80. On d57 a third unit of donor-1 CP was administered. Viral concentration dropped from 3.8 x 10⁷ copies/ml (d55) to 6.75 x 10⁴ copies/ml (d59, 2.75-log reduction). Infusion of three additional units of CP from a different donor (donor-2; d60, d62, d64; IgA/IgG OD-ratio: 8.58/6.44; NT-titer: 1:80) resulted in undetectable viral concentration on NP swabs and increased anti-SARS-CoV-2 antibodies in the patient’s serum above the detection limit (IgA/IgG OD-ratio: 2.78/2.96) (Figure 1). The patient’s symptoms cleared completely and SARS-CoV-2 RNA remained negative even after anti-SARS-CoV-2 antibodies decreased below the detection limit on day 111. The patient received the planned second HSCT on day 138 following conditioning with treosulfan (42g/m²). Despite this immunosuppressive and -modulatory procedure, the SARS-CoV-2-RNA was not detected by PCR on NP swabs or in the patient’s blood (last test from day 158).

Figure 2

Discussion

This unique case illustrates the course of COVID-19 in a situation where the functionality of innate and especially adaptive humoral and cellular immunity is severely limited. Development of COVID-19 pneumonia was significantly delayed despite high viral concentrations and only developed after partial recovery of the cellular immune response. As expected, viral clearance is not achieved with severely impaired T-cell and absent B-cell mediated responses (13, 14). This case and the detection of viral replication in cell culture beyond d50 highlights the need for prolonged quarantine measures and monitoring in patients with immune defects (6).

While remdesivir treatment reduced virus concentrations by 2.6-log, however, after stopping of the drug virus concentrations quickly recovered. CP administration from two different donors achieved sustained viral clearance even after anti-SARS-CoV-2 antibodies dropped below the detection limit, which is in line with reports from patients with primary and secondary immunodeficiency as well as with hematological malignancies (15–17). This therapeutic effect was retained even during a second HSCT on day 138. This case report underscores the importance of the humoral immune response, substituted here by CP transfusions, to successfully clear SARS-CoV-2 infection.

Funding

JT received acknowledges funding through BMBF B-FAST.

References

• 1

  NotarangeloLDKimMSWalterJELeeYN. Human RAG Mutations: Biochemistry and Clinical Implications. Nat Rev Immunol (2016) 16(4):234–46. doi: 10.1038/nri.2016.28

  • CrossRef
  • Google Scholar

• 2

  FischerANotarangeloLDNevenBCavazzanaMPuckJM. Severe Combined Immunodeficiencies and Related Disorders. Nat Rev Dis Primers (2015) 1:15061. doi: 10.1038/nrdp.2015.61

  • CrossRef
  • Google Scholar

• 3

  GoodallJWReedTANArdissinoMBassettPWhittingtonAMCohenDLet al. Risk Factors for Severe Disease in Patients Admitted With COVID-19 to a Hospital in London, England: A Retrospective Cohort Study. Epidemiol Infect (2020) 148:e251. doi: 10.1017/S0950268820002472

  • CrossRef
  • Google Scholar

• 4

  KimLGargSO’HalloranAWhitakerMPhamHAndersonEJet al. Risk Factors for Intensive Care Unit Admission and In-hospital Mortality Among Hospitalized Adults Identified Through the U.S. Coronavirus Disease 2019 (Covid-19)-Associated Hospitalization Surveillance Network (Covid-Net). Clin Infect Dis (2020). doi: 10.1093/cid/ciaa1012

  • CrossRef
  • Google Scholar

• 5

  AvanzatoVAMatsonMJSeifertSNPryceRWilliamsonBNAnzickSLet al. Case Study: Prolonged Infectious SARS-Cov-2 Shedding From an Asymptomatic Immunocompromised Individual With Cancer. Cell (2020) 183:1901–12. doi: 10.1016/j.cell.2020.10.049

  • CrossRef
  • Google Scholar

• 6

  AydilloTGonzalez-ReicheASAslamSvan de GuchteAKhanZOblaAet al. Shedding of Viable Sars-CoV-2 After Immunosuppressive Therapy for Cancer. N Engl J Med (2020) 383:2586–8. doi: 10.1056/NEJMc2031670

  • CrossRef
  • Google Scholar

• 7

  PaiSYLoganBRGriffithLMBuckleyRHParrottREDvorakCCet al. Transplantation Outcomes for Severe Combined Immunodeficiency, 2000-2009. N Engl J Med (2014) 371(5):434–46. doi: 10.1056/NEJMoa1401177

  • CrossRef
  • Google Scholar

• 8

  RuffnerMASullivanKEHenricksonSE. Recurrent and Sustained Viral Infections in Primary Immunodeficiencies. Front Immunol (2017) 8:665. doi: 10.3389/fimmu.2017.00665

  • CrossRef
  • Google Scholar

• 9

  DropulicLKCohenJI. Severe Viral Infections and Primary Immunodeficiencies. Clin Infect Dis (2011) 53(9):897–909. doi: 10.1093/cid/cir610

  • CrossRef
  • Google Scholar

• 10

  Al-HerzWEssaS. Spectrum of Viral Infections Among Primary Immunodeficient Children: Report From a National Registry. Front Immunol (2019) 10:1231. doi: 10.3389/fimmu.2019.01231

  • CrossRef
  • Google Scholar

• 11

  GreinJOhmagariNShinDDiazGAspergesECastagnaAet al. Compassionate Use of Remdesivir for Patients With Severe Covid-19. N Engl J Med (2020) 382(24):2327–36. doi: 10.1056/NEJMc2015312

  • CrossRef
  • Google Scholar

• 12

  BlochEMShohamSCasadevallASachaisBSShazBWintersJLet al. Deployment of Convalescent Plasma for the Prevention and Treatment of COVID-19. J Clin Invest (2020) 130(6):2757–65. doi: 10.1172/JCI138745

  • CrossRef
  • Google Scholar

• 13

  VardhanaSAWolchokJD. The Many Faces of the anti-COVID Immune Response. J Exp Med (2020) 217(6):e20200678. doi: 10.1084/jem.20200678

  • CrossRef
  • Google Scholar

• 14

  LiuSTHLinHMBaineIWajnbergAGumprechtJPRahmanFet al. Convalescent Plasma Treatment of Severe COVID-19: A Propensity Score-Matched Control Study. Nat Med (2020) 26:1708–13. doi: 10.1038/s41591-020-1088-9

  • CrossRef
  • Google Scholar

• 15

  SenefeldJWKlassenSAFordSKWigginsCCBostromBCThompsonMAet al. Therapeutic Use of Convalescent Plasma in COVID-19 Patients With Immunodeficiency. medRxiv (2020) 2020.11.08.20224790. doi: 10.1101/2020.11.08.20224790

  • CrossRef
  • Google Scholar

• 16

  ThompsonMAHendersonJPShahPKRubinsteinSMJoynerMJChoueiriTKet al. Convalescent Plasma and Improved Survival in Patients With Hematologic Malignancies and COVID-19. medRxiv (2021) 2021.02.05.21250953. doi: 10.1101/2021.02.05.21250953

  • CrossRef
  • Google Scholar

• 17

  HuesoTPouderouxCPéréHBeaumontA-LRaillonL-AAderFet al. Convalescent Plasma Therapy for B-cell–depleted Patients With Protracted COVID-19. Blood (2020) 136(20):2290–5. doi: 10.1182/blood.2020008423

  • CrossRef
  • Google Scholar